Tag: Drug Development

Sanofi Snags Vigil Neuroscience for Alzheimer's DrugSo, like, Sanofi, the French drug maker, just dropped $470 million to acquire Vigil Neuroscience, a small biotech company. And get this, they're adding an experimental treatment for...

Adam Feuerstein, a seasoned writer and biotech columnist, dives into the world of drug development, business, Wall Street, and biotechnology. He wears many hats as a co-host of the weekly biotech podcast The Readout...

In December 2024, a group of legal, medical, and public health experts united to file an amicus brief in support of the U.S. government in a groundbreaking patent lawsuit against Gilead Sciences Inc., a...

David Epstein, who previously served as the CEO of Seagen, has launched a new cancer startup called Ottimo Pharma. The company aims to develop a drug that targets two proteins, PD-1 and VEGF, in...

Seaport Therapeutics, a new biotech startup led by the team from Karuna Therapeutics, has successfully secured an additional $225 million in funding just half a year after its last fundraising effort. The Series B...

Alnylam Pharmaceuticals, led by CEO Yvonne Greenstreet, is making strides in expanding the use of its RNA-based gene-silencing heart drug, vutrisiran. The drug has shown promising results in reducing the risk of death and...

Good morning everyone, hope you had a restful weekend and are ready to tackle the new week ahead. As we sip on some refreshing blueberry cobbler, let's dive into some interesting updates. The U.S....

Albert Bourla, the CEO of Pfizer, is looking to shift the focus of the company from its successful COVID-19 vaccine and antiviral Paxlovid to new investments in drugs for cancer and obesity. While Pfizer's...

Good morning, this is Jonathan Wosen, reporting on the latest news in the biotech and life sciences world. The FDA has recently approved a new treatment for a rare soft tissue cancer. This cutting-edge...